[22]
Alhaique, F.; Riccieri, F.M.; Santucci, E.; Marchetti, M. 2,6-Naphthyridine derivatives from pyridoxine. Farmaco, 1983, 38(4), 242-247.
[40]
Hyvonen, M.J.; Break, P.; Spring, D.R.; Glossop, P. Preparation of benzo[ c][2,6]naphthyridine derivatives as casein kinase 2α inhibitors, compositions and therapeutic uses thereof. WO2022185041, 2022.
[57]
Lohani, S.; Peng, Z.; Mckeown, A.E. Synthesis of diazocino[2,1-a]naphthyridinetrione derivative in crystalline form. U.S. Patent US20080280945, 2008.
[58]
Han, W.; Egbertson, M.; Wai, J.S.; Zhuang, L.; Ruzek, R.D.; Perlow, D.S.; Obligado, V.E. Preparation of hydroxynaphthyridinediones as HIV integrase inhibitors. World Patent WO2005087767, 2005.
[59]
Matty, L., Jr; Wang, Y. Preparation of crystalline 6-(3-chloro-4-
fluorobenzyl)-4-hydroxy-2-isopropyl-N,N-dimethyl-3,5-dioxo-2,3,5,6,7,8-
hexahydro-2,6-naphthyridine-1-carboxamide sodium salt as an HIV integrase
inhibitor. World Patent WO2006107478, 2006.
[60]
Lee, M.S.; Jung, S.H.; Kim, T.U.; Ahn, Y.G. Preparation of 2,6-
naphthyridine-2-oxide derivatives as fibroblast growth factor receptor inhibitors. Korean Patent KR2019076339, 2019.
[61]
Ryckman, D.M.; Schwaebe, M. Polymorphs and salts of 5-(3-
chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid kinase inhibitor. World Patent WO2011063398, 2011.
[62]
Siu, T.; Young, J.; Altman, M.; Northrup, A.; Katcher, M.; Sathyajith, E.; Kozina, E.; Peterson, S.; Childers, M. Preparation of 7,8-fused-2,6-
naphthyridin-1(2H)-ones as inhibitors of janus kinases. World Patent
WO2009035575, 2009.
[79]
Dobler, M.R.; Jewell, C.F., Jr; Meredith, E.; Monovich, L.G.; Siska, S.; Von Matt, A.; Van Eis, M.; Yoon, T.; Gaul, C.; Capparelli, M.P. Preparation of [2,6]naphthyridines as protein kinase inhibitors. World Patent WO2008122615, 2008.